Financial Performance - For the six months ended December 31, 2022, revenue was approximately HKD 67.7 million, a decrease of about 7.2% compared to approximately HKD 73.0 million for the same period in 2021[5] - Profit before tax for the same period was approximately HKD 38.1 million, down approximately 9.9% from approximately HKD 42.3 million in the prior year[5] - Profit attributable to equity holders for the six months ended December 31, 2022, was approximately HKD 30.6 million, a decrease of about 8.7% from approximately HKD 33.5 million in the previous year[5] - The company reported a total comprehensive income of HKD 30.0 million for the six months ended December 31, 2022, compared to HKD 30.3 million in the previous year[8] - The total comprehensive income for the six months ended December 31, 2022, was HKD 30,271,000, a decrease from HKD 33,493,000 in the previous year[13] - The company reported a profit of HKD 30,581,000 for the six months ended December 31, 2022, compared to HKD 33,493,000 in the same period of 2021[13] Dividends - The board declared an interim dividend of HKD 15.0 million (HKD 0.0375 per share) to shareholders on the register as of March 17, 2023[5] - The company declared a dividend of HKD 20,000,000 for the year 2022, which was a reduction from HKD 30,000,000 declared for 2021[13] - The board declared an interim dividend of HKD 0.0375 per ordinary share, compared to HKD 0.025 per share for the same period last year[112] - The total amount of the interim dividend to be distributed is approximately HKD 15,000,000[112] - The interim dividend will be paid on March 23, 2023, to shareholders listed as of the close of business on March 17, 2023[112] Assets and Liabilities - Total assets as of December 31, 2022, were HKD 342.8 million, a decrease from HKD 351.3 million as of June 30, 2022[10] - Total liabilities decreased to HKD 122.1 million as of December 31, 2022, from HKD 140.7 million as of June 30, 2022[11] - The company's cash and bank balances decreased to HKD 42.3 million from HKD 86.3 million as of June 30, 2022[10] - The company's retained earnings increased to HKD 150,688,000 as of December 31, 2022, up from HKD 148,025,000 at the beginning of the period[13] - The total equity attributable to equity holders of the company increased to HKD 220,667,000 as of December 31, 2022, from HKD 194,787,000 at the beginning of the period[13] Cash Flow - The net cash generated from operating activities for the six months ended December 31, 2022, was HKD 5,923,000, a decrease of 91.4% compared to HKD 69,097,000 in the same period of 2021[14] - The net cash used in investing activities for the six months ended December 31, 2022, was HKD 3,128,000, a significant improvement from HKD (127,122,000) in the previous year[14] - The net cash used in financing activities for the six months ended December 31, 2022, was HKD (22,280,000), compared to HKD 53,542,000 generated in the same period of 2021[14] Revenue Breakdown - Revenue from healthcare staffing solutions for the six months ended December 31, 2022, was HKD 57,950,000, an increase of 10.3% from HKD 52,241,000 in the same period of 2021[27] - Total revenue for the group for the six months ended December 31, 2022, was HKD 67,689,000, a decrease of 7.5% compared to HKD 73,036,000 in the previous year[27] - Revenue from healthcare staffing solutions increased by approximately HKD 5.8 million or 11.1% to about HKD 58 million, primarily due to demand from COVID-19 testing agencies[60] - Revenue from outreach case assessment services decreased by approximately HKD 16.6 million to about HKD 4.2 million, mainly due to reduced demand for medical and health assessment services[60] - Institutional staffing solutions generated revenue of approximately HKD 45,300,000, representing a 27.3% increase from HKD 35,600,000 in the same period last year[64] Expenses - Total expenses for the group increased to HKD 218,749,000 in the six months ended December 31, 2022, from HKD 190,995,000 in the same period of 2021, representing a rise of 14.5%[29] - The cost of healthcare personnel accounted for HKD 160,799,000 of total expenses, up from HKD 138,754,000 in the previous year, marking an increase of 15.9%[29] - Employee benefits expenses were approximately HKD 13,400,000, an increase of about 6.3% from HKD 12,600,000 in the same period last year[68] Taxation - The company incurred a tax expense of HKD 7,549,000 for the six months ended December 31, 2022, compared to HKD 8,788,000 in the same period of 2021, a decrease of 14.1%[35] Corporate Governance - The board of directors has confirmed compliance with the corporate governance code throughout the reporting period[107] - The company maintains a high standard of corporate governance to protect the interests of shareholders and ensure effective management[108] - The roles of the chairman and CEO are currently held by the same individual, which deviates from the corporate governance code, but the board believes this structure is effective[109] Shareholder Information - The company’s major shareholder, Ms. Xi Xiaozhu, held a 67.55% equity interest in the company as of December 31, 2022[96] - Gold Empress holds 270,200,000 shares, representing 67.55% of the company's equity[101] - HRnet Group Limited owns 32,000,000 shares, accounting for 8.0% of the company's equity[101] Employment - The company employed a total of 69 employees as of December 31, 2022, a decrease from 72 employees as of December 31, 2021[90]
百本医护(02293) - 2023 - 中期财报